The FluidFM BOT Bio Series is the only instrument capable of measuring drug dose-response curves at a single-cell level, without the interference of a specifically designed delivery method. Researchers can now decouple drug response from side-effects caused by the delivery method, simplifying and optimizing the drug development process.
Using MRI to Diagnose Autism Spectrum Disorder
Using Microparticles to Repair and Detox Cardiac Muscle
How are Probiotic Formulations Validated?
Marburg Virus Structure and Transmission
Proteoforms in Drug Discovery
Manufacture and Composition of Micro-plates
Study reveals how serotonin balances communication within the brain
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines
Researchers gain new insight into how lipids function within tears
Study provides insights into how microbes protect gut health in early life
OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio
Scientists suggest practical steps to halt the decline of insect population
An Overview of Dopamine Receptor Pharmacology
What is the Skin Microbiome?
Deliver any compound into any adherent cell - easy and precise solution for your drug assay
Accelerate Your PCR Setup to Combat COVID-19
Controlled Ice Nucleation in the Pharmaceutical Industry
Examine Cell Mechanics With Fast Single Cell Force Spectroscopy
Dr. Andrew Webb
Dr. Andrew Webb describes how his lab uses mass spectrometry-based techniques to understand the role of post-translational modifications in human disease.
Dr Maureen Bunger
Lonza is a large, multinational corporation serving the entire pharmaceutical product development and manufacturing pipeline, from non-clinical research products to final dosage and delivery solutions.
Dr. Dan Lavery
News-Medical speaks to Dr. Dan Lavery about the LouLou Foundation, a non-profit organization dedicated to CDLK5 Deficiency Disorder.